HispanicBusiness

GAITHERSBURG, MD -- (Marketwire) -- 01/14/13 -- Cytomedix, Inc. (OTCQX: CMXI) (the "Company"), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that it has received the 2012 North American Frost & Sullivan New Product Innovation Award for its Angel® concentrated platelet-rich plasma (cPRP) system. This is an award that is presented each year by Frost & Sullivan to a company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features and benefits of the product and the increased return on investment it offers to customers.

Martin P. Rosendale, chief executive officer of Cytomedix, commented, "We are delighted to receive this award from Frost & Sullivan which recognizes the advanced technological features and commercial potential of our Angel system. Angel is positioned as a 'best in class' PRP device that represents a significant engineering advance in the separation of whole blood and bone marrow for clinical use and offers clear competitive advantages over other currently available systems."

"A unique feature of Angel is its flexible therapeutic output, which allows physicians to generate customized platelet concentrates at the point-of-care," said Aarti Shetty, research analyst at Frost & Sullivan. "Our analysis suggests that this is a product that could ultimately have broad use in a large number of orthopedic procedures."

The Angel cPRP System is intended to be used in the clinic or intraoperatively at the point-of-care for the safe and rapid preparation of platelet rich plasma (PRP). It was initially cleared by the FDA for whole blood processing and recently received 510K clearance to process bone marrow aspirate to produce platelet concentrates. The system is designed to produce consistently high platelet yields using a fully automated process and represents a significant engineering advance in autologous whole blood and bone marrow separation. Angel's advantages compared with other commercially available systems include: 1) high platelet yields, 2) significant reduction in pro-inflammatory cells, 3) rapid processing time, 4) adjustable hematocrit from 0%-25%, and 5) flexible final cPRP volumes. Proprietary software automatically adjusts the separation parameters to deliver a consistent, high quality product.

Frost & Sullivan Best Practices Awards are presented to companies in a variety of regional and global markets that have demonstrated outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Cytomedix, Inc.
Cytomedix, Inc. is an autologous regenerative therapies company commercializing innovative platelet technologies for orthopedics and wound care with a pipeline of adult stem cell therapies for tissue repair. The Company markets the AutoloGel™ System, a device for the production of autologous platelet rich plasma ("PRP") gel for use on a variety of exuding wounds and the Angel® cPRP System, a blood processing device and disposable products used for the separation of blood and bone marrow into red cells, platelet poor plasma ("PPP") and PRP in surgical settings. On February 8, 2012 Cytomedix closed the acquisition of Aldagen, a biopharmaceutical company developing regenerative cell therapies based on its proprietary ALDH bright cell technology, currently in a Phase 2 trial for the treatment of ischemic stroke. For additional information please visit cytomedix.com